| |OCTOBER 20239ELI LILLY & BOEHRINGER INGELHEIM ANNOUNCE US FDA NODS JARDIANCE TO TREAT ADULTS WITH CHRONIC KIDNEY AILMENTSIMAGEBIOPSY LAB, RADIOBOTICS PARTNER TO IMPROVE THE USE OF AI-POWERED TECHNOLOGIESJardiance (empagliflozin) 10 mg tablets have been approved by the US Food and Drug Administration (FDA) to reduce the risk of sustained decline in estimatedglomerular filtration rate (eGFR) end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney ailment (CKD) at risk of progression.Jardiance is not indicated for use in people with type 1 diabetes to enhance glycemic control. In these patients, it may raise the risk of diabetic ketoacidosis. Jardiance is not advised for usage in people with type 2 diabetes who have an eGFR less than 30 mL/min/1.73 m2. Based on its method of action, Jardiance is unlikely to be effective in this situation. Jardiance is not advised for the treatment of chronic kidney disease in patients with polycystic kidney disease, patients requiring or having a recent history of intravenous immunosuppressive medication, or patients requiring or having a recent history of prednisone or equivalent for kidney disease in doses greater than 45 mg. Jardiance will not be effective in these populations.Jardiance is not indicated for use in people with type 1 diabetes to enhance glycemic control. In these patients, it may raise the risk of diabetic ketoacidosis. Jardiance is not advised for usage in people with type 2 diabetes who have an eGFR less than 30 mL/min/1.73 m2. Based on its method of action, Jardiance is unlikely to be effective in this situation.Jardiance is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Jardiance is not expected to be effective in these populations, as per Indianapolis. POImageBiopsy Lab and Radiobotics have joined forces to improve the application of artificial intelligence (AI) enabled illness diagnoses in the DACH region for musculoskeletal (MSK), orthopaedic, and trauma use-cases. Musculoskeletal illnesses affect a bigger population than circulatory or respiratory diseases. Despite this, diagnostic approaches are frequently based on antiquated practices, such as manual interpretation of X-rays and MRI scans . These subjective and time-consuming approaches are not standardised and rely on practitioner knowledge.Despite an increasing number of MSK-specific solutions, consumers lack a comprehensive solution for a wide range of diagnostic needs. ImageBiopsy Lab and Radiobotics (both with MDR and FDA approvals) will collaborate to deliver a single, comprehensive solution for MSK imaging that includes measuring, scoring, and fracture detection workflow.Dr. Richard Ljuhar, CEO and co-founder of ImageBiopsy Lab, explains, "Before even considering the use of AI, it's crucial to grasp physicians' diagnostic workflow and needs. For this purpose we've closely collaborated with leading MSK radiologists, orthopaedics, and traumatologists over the past years. We're committed to revolutionizing the entire MSK diagnostic value chain for practitioners, patients, and healthcare systems. PO
< Page 8 | Page 10 >